Select your Country

Global
Africa
Asia
Europe
Latin America
North America
Oceania
Algeria
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Congo Democratic Republic
Djibouti
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Ivory Coast
Lesotho
Liberia
Libya
Madagascar
Malawi
Mauritania
Mauritius
Morocco
Namibia
Niger
Nigeria
Reunion Islands
Rwanda
Saint Helena
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Bahrain
Bangladesh
China
Hong Kong
India
Indonesia
Iran
Iraq
Israel
Japan
Jordan
Kuwait
Lebanon
Malaysia
Oman
Palestine
Philippines
Qatar
Saudi Arabia
Singapore
South Korea
Syria
Taiwan
Thailand
Turkey
United Arab Emirates
Vietnam
Yemen
Albania
Austria
Baltic Region
Belarus
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Macedonia
Netherlands
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
Ukraine
United Kingdom
Argentina
Aruba
Bahamas
Barbados
Belize
Bolivia
Brazil
Chile
Colombia
Costa Rica
Cuba
Curacao-NL Antillen
Ecuador
El Salvador
Guatemala
Haiti
Honduras
Jamaica
Mexico
Nicaragua
Panama
Paraguay
Perú
República Dominicana
Trinidad and Tobago
Uruguay
Venezuela
Canada
United States of America
Australia
New Zealand
Global
  • Company
  • Expertise
  • Research
  • Careers
  • Investors
Global
EN
Back
Company
Back
Expertise

Healthcare

Life Science

Performance Materials

Back
Research
Back
Careers
Back
Investors

What happened before 2014?

Are you searching for press releases published before 2014?

15 Jan 2008 | Darmstadt, Germany

Dear User,

To get press releases published before 2014,  please send an email to service@emdgroup.com.

Related News

Press Releases

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum ...

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin ...

2018/11/19

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy. Cookie Policy

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.